Which generation of targeted drug is Lorlatinib from Bangladesh Ziska Pharmaceuticals?

Lorlatinib/Lorlatinib is a third-generation targeted drug. Lorlatinib is used to treat a certain type of non-small cell lung cancer (NSCLC) in adults whose tumors have tested positive for anaplastic lymphoma kinase (ALK) with an FDA-approved test. Lorlatinib belongs to the kinase inhibitor class of drugs. It works by blocking the activity of abnormal proteins that are signals for cancer cells to reproduce, which helps prevent or slow the spread of cancer cells.

The recommended dose of lorlatinib is 100 mg orally once daily. Severe renal impairment: 75 mg orally once daily. The most common (incidence≥20%)adverse reactions and Grade 3-4 laboratory abnormalities with lorlatinib are edema, peripheral neuropathy, weight gain, cognitive effects, fatigue, dyspnea, arthralgia, diarrhea, mood effects, hypercholesterolemia, hypertriglyceridemia, and cough.

Currently, Lorlatinib produced by Bangladesh Ziskar Pharmaceuticals is also on the market and has government approval.100mg30The retail price of 100mg30 tablets is around 3 around 1,340, and the quality of the drug is guaranteed. Bangladesh Zisika Pharmaceuticals is a large pharmaceutical company in Bangladesh with a history of 35 years. All aspects of medicines are guaranteed. If necessary, patients can purchase it through regular domestic channels or go to Bangladesh Ziska Pharmaceutical Factory to purchase it themselves. The current factory retail price of generic drugs is 100mg30tablets3 about one thousand. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.